Autres langues MiNK Therapeutics, Inc.

Actions

INKT

US6036931029

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
0,98 ^USD	+1,09%		+5,66%	-8,41%

21/03	Transcript : MiNK Therapeutics, Inc., Q4 2023 Earnings Call, Mar 21, 2024
21/03	MiNK Therapeutics, Inc. annonce ses résultats pour le quatrième trimestre et l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report	30/04
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR	08/04
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR	08/04
MiNK Reports Fourth Quarter and Year-End 2023 Results	21/03
MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report	07/03
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report	07/03
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024	06/03
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024	06/03
MiNK Therapeutics, Inc. Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024	06/03
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab	14/02
MiNK Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study for agenT-797 in Second Line Gastroesophageal Cancer	14/02
MiNK Therapeutics, Inc. announced that it has received $5 million in funding from Agenus Inc.	12/02
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications	06/02
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications	06/02
Mink Therapeutics' Agent-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications	06/02
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene	30/01
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene	30/01
MiNK?s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene	30/01
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development	20/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues MiNK Therapeutics, Inc.

Actions

INKT

US6036931029

Autres langues

Filtres